Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
|Articles|February 27, 2012
FDA OKs First Drug-Eluting Stents for Use in MI
Advertisement
Two drug-eluting stents from Boston Scientific have become the first to be approved by the FDA for treating patients with acute myocardial infarction (AMI), the company announced.
The paclitaxel-eluting Ion and Taxus Liberté stents gained approval for AMI primarily on the strength of the evidence from the HORIZONS-AMI trial.
HORIZONS-AMI randomized 3,006 patients to bare-metal or Taxus stents. At three years, there were no significant differences in safety, including all-cause death, reinfarction, stent thrombosis, or stroke.
Read the full story:
Source: MedPage Today
Advertisement
Related to this article
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
4
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
5